Under the terms of the partnership, Millipore will gain exclusive rights to distribute Guava’s non-clinical instrumentation within defined fields in North America, Europe and other countries in Asia. Additionally, Millipore will provide field service for all Guava instrumentation in the same geographies. Millipore will also develop co-branded reagent kits specifically for Guava’s flow cytometers, Finally, Millipore and Guava Technologies will work together to develop a new generation of instrumentation that will offer scientists superior technical performance, higher quality data, and much greater accessibility than is currently available.
The combination of Millipore’s and Guava’s capabilities will integrate instrumentation, reagent kits, validated protocols, and technical support to bring the advantages of flow cytometry to the bench tops of cell biologists.
The parties plan to launch co-branded products to the market in July 2008.
Martin Madaus, president & CEO of Millipore, said: “The collaboration allows us to add considerable value to the highly differentiated antibody portfolio and assay development capabilities that came with our Serologicals acquisition.”